Managing Alcohol Withdrawal in General Hospitals

The COVID-19 pandemic triggered an unprecedented surge in alcohol consumption, leading to a significant rise in hospitalizations for alcohol withdrawal syndrome (AWS). For patients admitted to general hospitals, the sudden interruption of alcohol intake creates an iatrogenic risk for withdrawal, which can range from mild anxiety and tremors to life-threatening conditions like seizures and delirium tremens. Effective management begins with universal screening using validated tools like the Single Alcohol Screening Question (SASQ) or AUDIT-C. Beyond patient history, clinicians are increasingly utilizing direct biomarkers such as phosphatidylethanol (PEth), which can detect heavy drinking patterns over the previous month, to help risk-stratify patients and identify those at high risk for severe complications.

Pharmacological treatment remains centered on benzodiazepines, which effectively reduce the risk of seizures and delirium by modulating the GABAergic system. While symptom-triggered dosing is often preferred for lower-risk patients to minimize sedation, it may be inadequate for those at high risk or those already experiencing severe withdrawal. Phenobarbital has emerged as a robust alternative or adjunct, particularly for patients who are resistant to benzodiazepines or require intensive care. Additionally, supportive care must include aggressive nutritional repletion, specifically high-dose parenteral thiamine, to prevent irreversible neurological damage such as Wernicke-Korsakoff syndrome.

The goal of hospital care extends beyond acute stabilization to the prevention of future relapse. Initiating FDA-approved medications like naltrexone or acamprosate while the patient is still hospitalized—rather than waiting for a community referral—can significantly improve long-term outcomes and reduce readmission rates. While newer interventions like ketamine show promise for both withdrawal management and relapse prevention, further research is needed to refine individualized treatment protocols. Ultimately, a comprehensive approach that combines rigorous risk assessment, evidence-based pharmacotherapy, and proactive addiction treatment is essential for this vulnerable population.

https://www.bmj.com/content/bmj/388/bmj-2024-080461.full.pdf?utm_source=chatgpt.com